報價延遲最少15分鐘:2026/03/05 06:36 EST
盤前時段
|
||||
|
47.75 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
47.43
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.78/3.19
|
|
企業價值
28.91B
|
| 資產負債 |
|
每股賬面淨值
15.12
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
2.38B
|
|
每股收益
5.43
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
